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1. Introduction 
At increased concentrations compared to insulin, 
desoctapeptide insulin (DOP) and desasparagine 
desalanine insulin (DAA), resolved free of traces of 
insulin contamination, are inherently full insulin 
agonists in fat and muscle tissue [I]. These degraded 
insulins also act through the insulin receptor [I]. 
These findings indicate that if there is a discrete 
‘active center’ in the insulin molecule, it would appear 
to reside in the DOP core. In terms of insulin action, 
the relative importance of the ligand versus that of 
the insulin receptor and post-receptor events will not 
be considered here. 
Since the degraded insulins have such a markedly 
decreased capacity to bind to the insulin receptor, 
studies on role of the C-terminal portion of the 
B-chain of the insulin molecule become of consider- 
able interest. Studies of a human insulin variant with 
leucine substituted for phenylalanine at positions 24 
(and 25) also demonstrate a markedly decreased 
insulin activity and decreased binding indicating the 
importance of the C-terminal portion of the B-chain 
[2]. We found that the pentapeptide Arg-Gly-Phe- 
Phe-Tyr comprising residues B22-26 of insulin was 
biologically inactive alone but weakly potentiative of 
the actions of suboptimal concentrations of insulin or 
DOP [ 11. Now we report that at aloe4 M, the pep- 
tide alone is inactive, but markedly enhances both the 
biological activity of suboptimal concentrations of 
insulin (or DOP) and the specific binding of labelled 
insulin to its receptor. These effects require a peptide 
containing arginine. The enhanced binding is not due 
to decreased insulin degradation, but constitutes a 
true enhancement of the binding process itself. 
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2. Methods and materials 
Adipocytes were prepared from the epididymal 
tissue of 120-l 80 g rats (Wistar strain fed ad libitum). 
Adipocytes were either incubated in media for mea- 
surement of various metabolic or enzymatic para- 
meters or incubated in 125 I-labelled insulin for insulin 
binding. 14C02 production was measured as nmol D- [ l- 
14C]glucose to 14C02. lo6 cells-’ . h-l at 37°C as in 
131. For measurement of glycogen synthase activity, 
extracts were prepared [3] and glycogen synthase 
activity assayed as in [4]. Binding of labelled insulin 
was done as in ,[S]. 
1251-~be~ed insulin was obtained trout the 
courtesy of Dr George Vandenhoff from the Univer- 
sity of Virginia Diabetes Research and Training 
Center. Binding assays were conducted in the absence 
and presence of u~ab~lled insulin at 60 &ml fmal 
cont. 
UDP-glucose, glucose G-P, bovine serum albumin 
(fraction V) and rabbit liver glycogen were obtained 
from Sigma Biochemicals. The glycogen was purified 
before use by passing a 5% solution over a mixed-bed 
ion-exchange resin (Amber&e MB-3) as in [6]. 
Collagenase (Clostridium hjstozyticu~) was obtained 
from Worth~gton Biochemicals. Bacitracin was 
obtained from Pfizer. /3-Alanylpentapeptide amide 
was prepared as in [7]. Crystalline single-peak beef 
insulin (lot ID6-04-94-195) containing 0.49% pro- 
insulin and <0.003% glucagon, was obtained from Eli 
Lilly through the courtesy of Dr W. W. Bromer. 
[ 1 -‘4C]Glucose was obtained from New England 
Nuclear. DOP resolved free of trace insulin contami- 
nation was prepared as in [I ]. 
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Fig.1. Effect of varying concentrations of the p-alanyipenta- 
peptide amide on ‘“CO, production from gtucose in the 
absence and presence of insulin. Cells were isolated and 
washed in Krebs-Ringer phosphate buffer (pH 7.4) containing 
30 mg bovine serum albumin ml. [ I-“‘CjClucose conversion 
to “$CO, was measured after incubation of cells at 37’C for 
1 h in a medium containing 0.2 mM D-[I-‘*C~glucose with 
the indicated concentrations of the fl-alanylpentapeptide 
amide in the absence (0) and presence (0) of insulin (lo-‘* 
ML 
3. Results 
When r4C02 production from labelled glucose was 
measured as shown in fig.1, the &alanylpentapeptide 
amide containing B22 arginine of the B-chain was 
inactive alone over 10d--IO3 M. However in the 
presence of a submaximal concentration of insulin, 
at 10e4 M it stimuiated i4C02 production from glu- 
case 2-fold and at 10m3 M, 4-fold. Experiments with 
glycogen synthase activation were performed next. 
Fig.2 demonstrates that in the presence of a submaxi- 
mal concentration of insulin, the pentapeptide signi- 
ficantly stimulated glycogen synthase activation, an 
intracelluiarly mediated event [S]. Again the peptide 
alone was inactive. To determine whether the peptide 
was acting in the presence of suboptimal insulin con- 
centrations by decreasing insulin degradation, experi- 
ments were performed in the presence of bacitracin 
which itself is known to suppress insulin degradation. 
Fig.3 demonstrates that, in the presence of a sub- 
maximal concent:ation of insdin, the peptide stimu- 
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Fig.2. Stimulation of glycogen synthase activation by the 
P-alanylpentapeptide amide in the presence of insulin. 1 ml 
of cells (5 X 1 06) was incubated in the absence of glucose 
for 15 min at 37°C with or without 0.6 mM P-alanylpenta- 
peptide amide in the absence and presence of insulin (0.4 X 
lOi0 M), then centrifuged for 15 s in a clinicai centrifuge. 
After the medium had been aspirated, the incubation was 
terminated by adding 0.5 ml cold buffer (100 mM RF and 
10 mM EDTA, pH 7.0) to the cells. fotiowed by homogeni- 
zation at 0°C. After centrifugation at IO 000 X g for 15 min, 
the supernatants were used for enzyme assay. The results 
(expressed as % I activrty of glycogen synthase) are mean 
values from 3 independent expt. Maximal insulin value 
presented was obtained from ~ncubatjon of cells with 1 O-’ 
M insulin. 
3 
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Fig.3. Effect of the P-alanylpentapeptide amide on 14C0, 
production from [I -‘4C]giucose in the absence and presence 
of bacitracin. The incubations were conducted with or 
without 0.6 mM ~-alanylpen~~p~ptid~ amide and/or 1 mM 
bacitracin in the absence or presence of in&in (IO-” M). 
Other conditions were as in the legend to fig. 1. Error bars 
represent it 1 SD. 
162 
Volume 119. number 1 FE3S LETTERS September 1980 
lated f4C02 production from labelled glucose in the 
absence and in the presence of I mM bacitracin, 
which eliminates degradation of insulin [9]. We have 
confirmed this action of bacitracin by submitting reac- 
tion mixtures to Sephadex G-50 molecular sieving, 
which separates degraded from unaltered and aggre- 
gated insulin. With bacitracin present, no detectable 
insulin degradation occurred in the absence or pres- 
ence of P-alanyl pentapeptide amide. This was deter- 
mined by measuring the sizes of the 3 peaks present: 
peak 1, aggregated insulin; peak 2, native insulin; 
peak 3, degraded insulin. In the absence of bacitracin 
insulin degradation was clearly observed. The pres- 
ence of bacitracin itself also enhanced the effect of 
submaximal insulin, probably by protecting the 
hormone from degradation, 
To study further the mechanism of action of the 
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Fig.4. Effect of the ~-alanylpentape~tide amide on “‘I- 
labelled insulin binding to adipoytes. Cells (5 X 10’) in 
0.5 ml Krebs-Ringer phosphate buffer (pH 7.4) containing 
3% bovine serum albumin were incubated at 25°C for 30 min 
with ‘251-labelled insulin (0.7 X 10-r’ M spec. act. 1.2 
Ci/Mmol) in the presence of varying concentrations of the 
P-alanylpentapeptide amide in the absence of(o) and pres- 
ence of(*) cold native insulin (60 &ml). Aliquots (300 ~1) 
of tke ceI1 suspension were transferred to 400 r.d polyethyl- 
ene tubes containing 90 ~1 dinonly phthalate and rapidly cen- 
trifuged for 1 min in a Beckman microfuge (10 000 X g). 
After centrifugation, the tubes were cut through the oil layer 
and the ceUs transferred to counting vials and counted. 
peptide, we determined its effect on specific binding 
of labelled insulin to its receptor. Fig.4 demonstrates 
that the pentapeptide increased the specific binding 
of ‘251-labelled insulin to adipocyte receptors as a 
function of increasing concentration of the peptide. 
Furthermore, the concentration dependence of 
enhanced insulin binding is the same as that of 
enhanced insulin bioact~~ty. The B-chain C-terminal 
hetapeptide, Cly-Phe-Phe-Tyr-Pro-Lys derived 
from the C-terminal of B-chain, but without B22 
Arg, shawed no effect even in the presence of sub- 
maximal concentrations of insulin (not shown). Simi- 
lar experiments with suboptimal concentrations of 
DOP in place of insulin demonstrated analogous 
results to those with insulin (not shown). 
4. Discussion 
I-Iere, we have shown that ~-aIanyIpent~peptjde 
amide containing B22 Arg was inactive alone, but at 
lo4 M it potentiated the actions of insulin, including 
activation of r4C02 production from glucose and 
glycogen synthase activation. Even in the presence of 
bacitracin, under which conditions insulin degrada- 
tion was essentially completely suppressed, the pep- 
tide still stimulated insulin action, indicating that the 
peptide acts through a mechanism different from the 
protection of insulin from degradation. The concen- 
trations of peptide required for the st~ulation of 
insulin action correspond to those required for the 
increased binding. The close correlation between the 
biological potency and the effect on insulin binding 
strongly suggests that the stimulation of insulin ac- 
tion by the peptide may be directly related to 
increased binding of insulin to the insulin receptor. 
In [IO,1 I] evidence was presented that the pep- 
tides derived from the C-terminal of the B-chain of 
insulin containing arginine were active alone. The 
~sulin-like activity of the peptide alone reported in 
[ lo,1 I], however, was more notable when the experi- 
ments were performed in whole animals or with tis- 
sues rather than with cetls. For example, the activity 
of the peptide was much lower with adipocytes com- 
pared with diaphragm, despite the fact that adipocytes 
are well known to be one of the cells most sensitive 
to insulin [3]. Their results can be more reasonably 
interpreted therefore, if we assume that the insulin- 
like activity of the peptide is not due to an inherent 
activity of the peptide per se, but due to potentiation 
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by the peptide of the action of endogenous insulin or 
degraded insulin present in the animals or tissues 
used. Taken together with our data demonstrating the 
DOP is fully active in terms of maximal response, it 
was concluded that DOP contains the ‘active center’ 
of the insulin molecular if indeed there is a single 
‘active center’ and the C-terminal peptide of the 
B-chain isnot the ‘active center’ alone, but potentiates 
insulin action. Studies are underway detailing the 
kinetics of the effects of the peptide on the associa- 
tion and dissociation rate processes in insulin binding 
and will be reported subsequently. These peptides 
should now prove valuable as probes in studying 
insulin receptor function in insulin action. 
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